Illustration: Sarah Grillo/Axios
Aktis Oncology, a biotech developing targeted radiopharmaceuticals for solid cancer tumors, raised $318 million in its IPO at $18 per share.
Why it matters: Boston-based Aktis is the first notable biotech to go public since Evommune's (NYSE: EVMN) debut in November.
